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SUMMARY
Here, we detail our optimized protocol for the identification of drug targets in
Leishmania donovani using thermal proteome profiling. This approach is based
on the principle that binding of a drug to its protein target can significantly alter
the thermal stability of that protein. By monitoring changes in the thermal stabil-
ity of proteins within drug-treated and untreated cell lysates, using mass spec-
trometry combined with tandem mass tag labeling, putative targets of the
drug can be identified in an unbiased manner.
For further details on the use and application of this protocol, please refer to Pa-
radela et al. (2021).
BEFORE YOU BEGIN
The protocol below describes the specific steps for TPP analysis of Leishmania donovani LdBOB pro-
mastigotes (derived from MHOM/SD/62/1S-CL2D). However, we have also used this protocol to
investigate compound interactions in other kinetoplastid parasites, specifically Trypanosoma brucei
and Trypanosoma cruzi. Prior to beginning the study, prepare 1 L of LdBOB promastigotemedia and
pre-warm to room temperature (RT; 20C–25C).
A rationalized version of this protocol, without compound pre-treatment of parasites or lysate prep-
aration in the presence of detergent, has also been published previously (Corpas-Lopez et al., 2019).
L. donovani promastigote culture
Timing: 3 days
1. Inoculate 1 L of LdBOBmedia with L. donovani (LdBOB) promastigotes at 13 105 cells mL1. Split
the culture into two Corning roller bottles (500 mL each). Incubate these bottles in a humidified
roller bottle incubator with rotation at 28C for 72 h or until cultures reach mid-logarithmic (mid-
log) growth. Roller bottles are recommended for cultures of this size since the constant rotation of
flasks provides optimal aeration.
CRITICAL: Monitor cell density in roller bottle cultures daily and do not allow cells to reach
stationary phase (43 107 mL1). For LdBOB promastigotes in our media, mid-log growth
is considered between 8 3 106–2 3 107cells mL1. It should be noted that mid-log growth
may vary for different species of Leishmania and/or culture medium.
STAR Protocols 2, 100704, September 17, 2021 ª 2021 The Author(s).




Alternatives:Use conventional cell culture flasks instead of roller bottles. In this case, culturesmay
need to be separated intomultiple flasks to ensure sufficient aeration and optimal parasite growth
Prepare and pre-chill material
Timing: 1 h
2. Prepare Lysis Buffer (10 mL; see the detailed recipe in ‘‘materials and equipment’’) and store at
4C until required.
3. Pre-chill the ultracentrifuge, rotors, tubes and LoBind tubes to 4C.
KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Chemicals, peptides, and recombinant proteins
Potassium phosphate monobasic Sigma P5655
Potassium phosphate dibasic Sigma P3786
Ethylenediaminetetraacetic acid (EDTA) Sigma E9884
1,4-Dithiothreitol (DTT) Sigma 10708984001
M199 media Sigma M0393
Fetal bovine serum (FBS) Fisher Scientific 12350273
Sodium bicarbonate Sigma S5761
GlutaMAX Invitrogen 35050087
Folic acid Sigma F8758
Adenosine Sigma A9251
Hemin Sigma 51280
Lysyl Endopeptidase, Mass Spectrometry Grade Alpha Labs (Wako) 125-02543
Trichloroacetic acid solution 6.1 N Sigma-Aldrich T0699
cOmplete, Mini, EDTA-free Protease Inhibitor Cocktail Roche 11836170001
Octyl b-D-glucopyranoside Sigma-Aldrich O8001
Na-Tosyl-L-lysine chloromethyl ketone hydrochloride (TLCK) Sigma-Aldrich T7254
Acetone R99.8%, AnalaR NORMAPUR ACS VWR 20066.330
Pierce Acetonitrile (ACN), LC-MS Grade Thermo 51101
Formic acid, LC-MS Grade Thermo 85178
Acetonitrile, HPLC LC-MS Grade VWR 20J141963
Trifluoroacetic acid, HPLC Grade Fisher T/3258/04
Ammonia solution, OPTIMA Grade Fisher A470-250
Methanol (OPTIMA LC/MS) Fisher A456-1
Ammonium formate Sigma 70221-100G-F
pH-indicator strips pH 0–14 Universal indicator Sigma 1095350001
Dimethyl sulfoxide, molecular biology grade Sigma D8418
Critical commercial assays
TMT10plex Isobaric Mass Tagging Kit Thermo 90111
Tris(2-carboxyethyl)phosphine (TCEP) N/A N/A
Iodoacetamide (IAA) N/A N/A
Triethylamonium bicarbonate (TEAB) N/A N/A
Trypsin N/A N/A
Quenching reagent (50% hydroxylamine) N/A N/A
Pierce Peptide Desalting Spin Columns Thermo 89852
Quick Start Bradford Protein Assay Bio-Rad 5000201
Experimental models: Organisms/strains
Leishmania donovani LdBOB (MHOM/SD/62/1S-CL2D) (Goyard et al., 2003) N/A
Software and algorithms
Thermo XcaliburTM Thermo Version 4.0.27.19
ChromeleonTM Software Thermo Version 4.0.27.19
(Continued on next page)
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MATERIALS AND EQUIPMENT
Suggested equipment and material
One-Shot cell disruptor (Constant Systems, OS)
Tabletop Optima TLX Ultracentrifuge (Beckman, TLX)
Rotors TLA 100 Fixed angle rotor (Beckman, 343840) and TLA 120.0 Fixed angle rotor (Beckman,
362046).
Sonicator Elmasonic P60H (Elma, 101 3761)
Vibrax VXR basic shaker (IKA, 0002819002)
Genevac EZ-2 plus evaporator (SP Scientific, EZ3P-23050-HP0)
Dionex UHPLC Ultimate 3000, WPS-3000FC autosampler (Thermo Scientific, 5825.0020)
C18 column XBridge peptide BEH, 130 Å, 3.5 mm, 2.1 3 150 mm (Waters, 186003565)
Guard column XBridge, C18, 3.5 mm, 2.1 3 10 mm (Waters, 186003019)
PepMap nanoViper C18 column, 100 mm 3 2 cm, 5 mm, 100 Å (Thermo Scientific, 164564-CMD)
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
MaxQuant version 1.6.17.0 Tyanova et al., 2016 Maxquant.org
Analyze thermal proteome profiling (TPP) experiments. R package
version 3.18.0
Childs et al., 2020 https://bioconductor.org/packages/
release/bioc/html/TPP.html
Script to analyze MaxQuant results in TPP Victoriano Corpas-Lopez https://github.com/vcorpaslopez/
StarProtocolsTPP
Deposited data
RAW and search files of the project PRIDE repository https://www.ebi.ac.uk/pride/archive/
projects/PXD023780
Other
Tabletop Optima TLX Ultracentrifuge Beckman TLX
One-Shot Cell Disruptor Constant Systems OS
TLA 100 Fixed-angle rotor Beckman 343840
TLA 120.0 Fixed-angle rotor Beckman 362046
Sonicator Elmasonic P60H Elma 101 3761
Vibrax VXR basic shaker IKA 0002819002
Genevac EZ-2 plus evaporator SP Scientific EZ3P-23050-HP0
Dionex UHPLC Ultimate 3000, WPS-3000FC Autosampler Thermo Scientific 5825.0020
C18 column XBridge Peptide BEH, 130 Å, 3.5 mm, 2.1 3 150 mm Waters 186003565
Guard column XBridge, C18, 3.5 mm, 2.1 3 10 mm Waters 186003019
PepMap nanoViper C18 column, 100 mm 3 2 cm, 5 mm, 100 Å Thermo Scientific 164564-CMD
PepSwift Monolithic Nano resolving column Thermo Scientific 164584
Thermo Q Exactive Plus Orbitrap System coupled to a Dionex Ultimate 3000 RS Thermo Scientific IQLAAEGAAPFALGMBDK
Thermo Q Exactive HF Orbitrap System coupled to a Dionex Ultimate 3000 RS Thermo Scientific IQLAAEGAAPFALGMBFZ
Resolving column, 75 mm 3 50 cm, PepMap RSLC C18 column, 2 mm, 100 Å Thermo Scientific 164540
Corning 1700 cm2 Roller Bottles, Tissue Culture Treated Corning CLS430852
Protein LoBind tubes (0.5, 1.5 and 2 mL) Eppendorf 0030108434, 0030108442,
0030108450
Open-top 230 mL thickwall polycarbonate centrifuge tubes 7 3 20 mm Beckman 343775
Open-top 1 mL thickwall polycarbonate tubes, 11 3 34 mm Beckman 342778
1.5 mL Collection tubes SARSTEDT 72.696
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Pepswift Monolithic Nano resolving column (Thermo Scientific, 164584)
Thermo Q Exactive Plus Orbitrap System coupled to a Dionex Ultimate 3000 RS (Thermo Scientific,
IQLAAEGAAPFALGMBDK)
Thermo Q Exactive HF Orbitrap System coupled to a Dionex Ultimate 3000 RS (Thermo Scientific,
IQLAAEGAAPFALGMBFZ)
Resolving column, 75 mm3 50 cm, PepMap RSLCC18 column, 2 mm, 100 Å (Thermo Scientific, 164540)
Corning 1700 cm2 roller bottles, tissue culture treated (Corning, CLS430852)
Protein LoBind tubes (0.5, 1.5 and 2 mL) (Eppendorf, 0030108434, 0030108442, 0030108450)
Open-top 230 mL thickwall polycarbonate centrifuge tubes 7 3 20 mm (Beckman, 343775)
Open-top 1 mL thickwall polycarbonate tubes, 11 3 34 mm (Beckman, 342778)
1.5 mL collection tubes (Sarstedt, 72.696)
Choice of mass spectrometer: This TPP protocol relies on TMT quantitation, therefore a successful
TPP analysis would then need an instrument compatible with this technology. We use a Q Exactive
HF instrument, but other machines can be used as long as their MS/MS resolution is > 50,000 at 150
m/z and can perform higher-energy collision dissociation (HCD). Suggested equipment includes Or-
bitrap Velos Pro, Q Exactive, Q Exactive Plus, Orbitrap Elite, Orbitrap Fusion and Orbitrap Eclipse
(as recommended in the TMT 10plex instructions).
Note: use freshly prepared buffer and keep on ice.
Lysis Buffer
Reagent Final concentration Amount
Mono-basic potassium phosphate, 200 mM stock 50 mM 1.0 mL
Di-basic potassium phosphate, 200 mM stock 50 mM 1.5 mL
0.5 M EDTA 1 mM 0.05 mL
1 M DTT 1 mM 10 mL
Protease inhibitor cocktail mini tablet, EDTA-free 1 tablet
10 mM Tosyl-L-lysyl-chloromethane hydrochloride (TLCK) 100 mM 0.1 mL
n-octyl-b- d-glucoside 0.8% 80 mg
ddH2O - 7 mL
Total - 10 mL
LdBOB Promastigote Media
Reagent Final concentration Amount
M199 media - 1 sachet
FBS 10% 100 mL
Sodium bicarbonate 1 g/L 1 g
Glutamax (1003 stock) 13 10 mL
Folic acid 4.4 mg/L 4.4 mg
Adenosine 27 mg/L 27 mg
2.5 mg/mL Hemin 10 mg/L 4 mL
ddH2O - 900 mL
Total - 1000 mL
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Note: store at 4C for a maximum of 1 month.
STEP-BY-STEP METHOD DETAILS
Incubation of L. donovani promastigotes with test compounds
Timing: 3.5 h
This section details pre-incubation of L. donovani promastigotes with test compound prior to sam-
ple processing. Exposing parasites to test compounds for a short period, prior to processing, en-
ables the compound to interact with its target in a native conformation, potentially increasing the
chances of thermal stabilization of the target.
1. Add the test compound to one of the roller-bottle cultures (treated sample, 500 mL) at a concen-
tration equivalent to 103 its established EC50 value. It should be noted that compound stocks
must be prepared so that the vehicle (commonly DMSO) does not exceed a final concentration
of 0.5% in treated cultures. An equivalent volume of the diluent should be added to the second
roller-bottle (control sample, 500 mL).
2. Treated and untreated cultures should be returned to the incubator at 28C for a further 3 h.
CRITICAL: The EC50 value of the test compound should be accurately determined prior to
the study. Adding test compound in excess of 103 EC50 value could result in parasite cell
death and lysis with the concomitant release of damaging proteases that will affect the
sample quality. Incubation with excessively high compound concentrations may increase
the likelihood of off-target compound interactions. Incubation with test compounds at
lower concentrations may lead to sub-optimal thermal stabilization of specific targets.
Generation of cell lysate
Timing: 2 h
This protocol describes how to prepare cell lysates suitable for subsequent TPP studies.
3. Centrifuge (1920 3 g for 15 min at 4C) the 500 mL treated and control cultures of L. donovani.
Wash the resulting cell pellets (0.2–0.5 mL expected pellet volume) with the equivalent of 5 pellet
volumes of ice-cold PBS and then centrifuge (1920 3 g for 15 min at 4C). It should be noted that
the PBS used for cell pellet washes should be spiked with either test compound or vehicle at con-
centrations equivalent to those used in pre-incubations.
CRITICAL: It is important to maintain the presence of the test compound (in the treated
sample) or diluent (in the control) throughout cell pellet washes. This ensures that
target-ligand interactions made during the initial incubation are maintained.
4. Resuspend washed parasite pellets in 2 mL ice-cold lysis buffer (again supplemented with test
compound at a concentration equivalent to 103 its established EC50 value or diluent) and transfer
to LoBind tubes (5 mL).
CRITICAL: At this stage it is vital to use LoBind tubes to prevent loss of protein from the
samples due to non-specific binding to plastic. It is also important to maintain samples
on ice.
5. Lyse cells under pressure using the Constant Systems cell disruptor. It should be noted that other
methods of cell lysis, such as sonication or nitrogen cavitation, may be equally suitable.
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a. Pre-chill the cell disruptor lysis chamber to 4C.
b. Lyse the control sample at a pressure of 30 kpsi.
c. Wash the cell disruptor lysis chamber 23 with milliQ H2O (5 mL) and 13 with lysis buffer (5 mL)
to prevent cross contamination of samples.
d. Then lyse the treated sample at 30 kpsi.
6. Transfer cell lysates into 1 mL tubes suitable for ultracentrifugation and centrifuge (100,000 3 g
for 20 min at 4C). Recover the supernatant from centrifuged samples and transfer into a fresh
2 mL LoBind tube. Do not disturb the pellet when recovering the supernatants. The pellets can
now be discarded.
7. Accurately determine protein concentration of the supernatants using a standard Bradford or
similar protein assay. Adjust the protein concentration of each sample (treated and control) to
1–1.5 mg/mL using ice-cold Lysis Buffer. The protein yield required for a single TPP experiment




This protocol describes the steps required to perform thermal shift assays. Here, treated and control
lysates are exposed to a range of temperatures. The proteins within each sample denature at
different points of the temperature gradient and ultimately precipitate. Precipitated proteins are
then removed by ultracentrifugation and the soluble fraction is assessed.
8. Dispense the treated and control cell lysates into 10 3 0.5 mL LoBind tubes (100 mL aliquots in
each tube, representing 100–150 mg of protein) making two series per condition (treated and con-
trol) each comprised of 10 samples. Keep these tubes on ice.
Note: Individual aliquots will be incubated at a single temperature point within the following
temperature range: 33C–69C in 4C increments.
Note: A thermal cycler or gradient PCR machine can be used to achieve an accurate temper-
ature gradient. If you do not have access to a gradient PCRmachine, a standard thermal cycler
can be used sequentially.
9. Submit the aliquots to the following temperatures: 15 min at room temperature (RT, 20C–
25C), 3 min at the designated temperature point, 3 min at room temperature and then place
on ice.
10. Transfer the contents to open-top thickwall 230-mL ultracentrifuge tubes (Beckman) and remove
denatured proteins by ultracentrifugation (100,000 3 g, 4C for 20 min). Carefully harvest the
supernatants and transfer to fresh 1.5 mL LoBind tubes. Discard the pellets.
CRITICAL: It is imperative that supernatants are harvested carefully and that they are not
contaminated with material from the pellet. Do not attempt to recover all of the superna-
tant, we suggest that the maximum volume that can be safely recovered is 70 mL.
11. Measure protein concentration in each sample using the Bradford or similar protein concentra-
tion assay.
12. Plot the determined protein concentrations of each sample against the temperature each sam-
ple was exposed to. It is expected that as the exposure temperature increases the level of recov-
ered protein should decrease.
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Note: The protein concentration of the sample exposed to the highest temperature in the
range (in this case 69C) should be <20% of that in the sample exposed to the lowest temper-
ature. Troubleshooting 2.
Sample processing and labeling
Timing: 3–4 days
This section describes the process of reducing, alkylating and denaturing samples. In addition, the
process of digesting and labeling peptides with TMT 10-plex tags is detailed.
CRITICAL: Trifluoroacetic acid (TFA) and formic acid (FA) are harmful when inhaled. They
need to be used in an fume hood to minimize the risk of inhalation and disposed following
the appropriate health and safety regulations.
13. To reduce each sample add 25–50 mM tris(2-carboxyethyl)phosphine hydrochloride (TCEP,
3.5 mL 1M TCEP) and incubate for 10 min at 37C. Allow the samples to equilibrate to RT
(20C–25C).
14. To alkylate proteins, add 25–50 mM iodoacetamide (IAA, 3.5 mL 1M IAA) to each sample and
incubate for 1 h at RT (20C–25C) in the dark.
Note: Some precipitation may be seen after incubation with IAA.
CRITICAL: Use a fresh IAA solution and preserve it from light. Foil can be used to protect
alkylated samples and IAA solution from light.
15. To precipitate proteins, add 10.5 mL trichloroacetic acid 6.1 N (TCA, final concentration of 12%)
to each sample, vortex briefly (5 s) and incubate samples at 20C for a minimum of 3 h. Sam-
ples can be left at 20C overnight (3–16 h).
Note: Some samples may be frozen following overnight incubation. Allow frozen samples to
melt on ice prior to the next step.
16. Centrifuge (20,0003 g, 4C for 5 min) samples, then carefully discard the supernatants and har-
vest the pellets. Place the tubes containing the pellets on ice.
Note: Samples must be kept on ice during the acetone washes.
17. Add pre-chilled acetone (500 mL) to each pellet, then vortex (10 s) until the pellet is dislodged
from the bottom of the tube. Now incubate at 4C for 10min with agitation (600 rpm) in a shaker.
18. Next, centrifuge (20,000 3 g, 4C for 5 min) each sample, carefully remove and dispose of the
acetone. Repeat washes 23 with acetone.
Note: During washes be careful not to disturb or aspirate the pellet. It is not essential to re-
move all the acetone since any excess can be removed by evaporation.
19. Finally, remove and dispose of the acetone and leave pellets to air dry at RT (20C–25C).
Optional: Acetone evaporation can be accelerated by incubation at 37C.
Pause point: At this time, protein pellets can be safely stored at 20C.
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20. Resuspend the pellets in 100 mM tetraethylammonium bicarbonate pH 8.5 (TEAB, 500 mL). Vor-
tex each sample vigorously (20 s) until pellets are dissolved.
Note: Following resuspension of the pellet, check the pH of the sample is R8 using a pH in-
dicator strip.
Note: if the pellets are very stubborn and they do not dissolve, try sonication in a sonicating
water bath for 5 min (37 kHz, 100% power, RT (20C–25C)) to help dissolve the pellet before
adding the digestion enzymes.
21. In order to resuspend the desiccated vial of endoproteinase Lys-C, add 100 mM TEAB (20 mL)
and shake gently to make a 1 mg/mL solution.
22. Add resuspended Lys-C solution to each sample at a 50:1 protein:enzyme ratio (1 mg of enzyme
per 50 mg of protein). Incubate with agitation (600 rpm) at 37C for 4–6 h.
Note: Use protein concentration quantified in step 11 to calculate the amount of Lys-C and
Trypsin required (approximately 1.4–2.1 mg of enzyme per tube).
23. In order to resuspend the desiccated vial of trypsin, add 100 mM TEAB (20 mL) to the vial and
shake gently to make a 1 mg/mL solution.
24. Add trypsin solution to the samples at a 50:1 protein:enzyme ratio. Incubate at 37C with agita-
tion (600 rpm) for between 8–16 h.
25. Vacuumdry the samples in an evaporator overnight (8–16 h) at 30C using a program suitable for
water-based samples (program ‘‘Aqueous’’ in the recommended evaporator).
Optional: We recommend checking the digestion efficiency of some of the samples via mass
spectrometry prior to TMT labelling.
26. To check the digestion efficiency, randomly select a few (2–4) samples representative of
different temperatures (for example samples 1, 5 and 9) as they have different protein quantity.
a. Resuspend these samples in 100 mL TEAB, then pick a 1 mL aliquot and dilute it 1:5 in 0.1% FA
in a sample tube.
b. Use the following recommended equipment: Q Exactive Plus mass spectrometer coupled to
a Dionex Ultimate 3000 RS (Thermo Scientific) equipped with a trap column (100 mm 3 2 cm,
PepMap nanoViper C18 column, 5 mm, 100 Å, Thermo Scientific) and a Pepswift Monolithic
Nano resolving column.
c. Place each sample in the sample rack of the HPLC and load 5 mL sample at 10 mL min1 onto
the trap column pre-equilibrated with Buffer C. Wash the trap column with Buffer C for 3 min
at 10 mL min1, then switch the trap column in line with the resolving column. Elute peptides
at a constant flow rate of 700 nL min1 with a linear gradient from 2%–40% Buffer D over
7 min, and then from 40%–98% Buffer D over 1 min. Wash the column with 98% Buffer D
for 1 min and re-equilibrate in 2% Buffer D for 5 min.
d. Use Q Exactive Plus in data-dependent positive ion mode using the following setup:
i. MS1 scan cycles m/z range from 335–1800, with a maximum ion injection time of 30 ms, a
resolution of 70,000 and automatic gain control (AGC) value of 1 3 106.
ii. Followed by 10 sequential dependent MS2 scans with an isolation window set to 1.4 m/z,
resolution at 17,500, maximum ion injection time at 100 ms and AGC 2 3 105.
e. Open the .raw files using Thermo XcaliburTM (Qual browser). This should open two windows:
the upper window showing a chromatogram of signal relative abundance over retention time
and the lower window showing the relative abundance over m/z ratio.
f. By selecting peaks on the upper chromatogram, the lower window will display the relative
abundance and m/z of that peak.
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Note: Check that the majority of peaks have a charge lower than 4 (z <4). High abundance of
multiply charged species indicate that digestion has been not accomplished and should be
repeated.
Pause point: Digested peptides can be stored at 20C.
27. TMT 10plex labels are provided in sachets stored at 20C. Remove 4 3TMT 10plex sachets
from storage at 20C and allow to equilibrate to RT (20C–25C). Each sachet contains 10
tubes with 0.8 mg of the corresponding TMT 10plex label, enough to label 100 mg of protein.
Note: It is important that the 43 sachets should share the same batch number since there can
be variability between batches.
28. Resuspend the dried peptide samples in 100 mM TEAB (100 mL) and incubate at RT (20C–25C)
with agitation (600 rpm).
Note: Check that the pH of samples is R8
29. Add acetonitrile (ACN, 41 mL) to each TMT tube and incubate with agitation (600 rpm) for 15min
at RT (20C–25C).
30. Briefly, centrifuge peptide samples and TMT tubes (3,000 3 g, 10 s).
31. Add the content of each TMT tube to the corresponding peptide sample, as follows:
32. Incubate with agitation for 1 h at RT (20C–25C).
33. Dilute the quenching reagent (50% hydroxylamine solution) 10-fold in 100 mM TEAB, making a
final 5% hydroxylamine solution.
Note: If the quenching reagent appears precipitated, incubate at 37C until the solution
clears.
34. In order to quench the residual, unreacted TMTs, add 5% hydroxylamine solution (8 mL) to each
reaction tube and incubate with agitation.
35. Briefly centrifuge (3,000 3 g, 10 s) each reaction tube and then combine the 103 treated sam-
ples together in a single LoBind 2 mL tube. Then combine the 103 control samples into another
2 mL LoBind tube.
36. Vacuum dry the pooled samples in an evaporator overnight (8–16 h) at 30C using a program
suitable for water and organic solvent-based samples (program ‘‘HPLC’’ in the recommended
evaporator).
Pause point: TMT-labelled peptides can be stored at 20C.
37. To start the desalting step, resuspend the dried pooled samples in 0.1% TFA (300 mL).
38. Place the desalting columns (one per sample) in 2 mL LoBind tubes and centrifuge (5,000 3 g,
1 min) to remove the equilibration buffer. Discard the flow through.
39. Wash the desalting columns 23 with 100% ACN (300 mL) and discard the flow-through.
40. Wash the columns a further 23 with 0.1% TFA (300 mL) and discard the flow-through.
Sample 1 2 3 4 5 6 7 8 9 10
Temperature (C) 33 37 41 45 49 53 57 61 65 69
TMT label 126 127N 127C 128N 128C 129N 129C 130N 130C 131
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41. Add the samples to separate desalting columns, centrifuge (3,000 3 g, 1 min) and discard the
flow-through. The peptides should now be bound to the columns.
42. Wash the columns 33 with 0.1% TFA and discard the flow-through.
43. Wash the columns 23 with 5% methanol (diluted in 0.1% TFA) to remove excess TMTs.
44. Elute peptides from the desalting columns into fresh 2 mL LoBind tubes by centrifugation (3,000
3 g, 1 min) using 50% ACN diluted in 0.1% TFA (23 300 mL).
45. Vacuum dry the desalted eluates.
Pause point: Desalted TMT-labelled peptides can be stored at 20C.
Sample fractionation and mass spectrometry analysis
Timing: 10 days
This section describes the fractionation of samples by high-pH reverse-phase high performance
liquid chromatography (RP-HPLC). Fractionation enables less complex peptide samples to be pre-
pared for subsequent analysis by LC-MS/MS.
46. Set-up of the Ultimate 3000 HPLC (Dionex) using the Chromeleon software.
a. Turn on UV lamp (wavelength 220 nm) at least 15 min prior to a run.
b. Purge the system with Buffer A (10 mM ammonium formate, pH 9.5) and Buffer B (10 mM
ammonium formate in 90% ACN, pH 9.5).
c. Set the buffer composition to 98% A:2% B and the flow rate to 0.2 mL min1.
d. Prime the syringe and wash the needle and fluidics.
e. Run the HPLC under these conditions for 15 min to fully equilibrate the system.
47. Run a standard containing caffeine andMRFA (Met-Arg-Phe-Ala peptide) to check the HPLC sys-
tem is working correctly.
a. Place collection tubes in the collection trays.
b. Prepare the standard sample by diluting 2 mL of caffeine solution (1 mg/mL) andMRFA (1 mg/
mL) in 100 mL buffer A in a HPLC sample tube. Place the sample tube in the samples tray.
c. Run the sample using the following program:
i. Load 25 mL sample in the column.
ii. Elute peptides from the column with a gradient of 2–20% Buffer B over 8 min.
iii. Over the following 37 min increase the % of Buffer B from 20 - 47%.
iv. Wash the column with 100% Buffer B for 15 min.
v. Fractions (volume) should be collected from 1 – 80 min of the run.
d. Discard the collected fractions from the standard run.
e. Check the chromatogram for two peaks in minutes 12 and 14 that correspond to caffeine and
MRFA respectively.
48. Prepare and run the first sample
a. Resuspend the dry sample in 200 mL buffer A, vortex vigorously and then spin down at
20,000 3 g 4C for 15 min. Transfer 190 mL of supernatant to the sample tube and adjust
to pH >9 using ammonia (check pH with a pH strip). Place the transfer tube in the sample tray.
b. Label 80 collection tubes and add 20 mL 10% FA to neutralize the pH of the fraction eluates.
Place the collection tubes in the collection trays.
c. Run the sample using the program detailed in 46c but loading 185 mL sample.
d. Combine the 80 resulting fractions into 20 fractions by concatenating them. Discard fractions
1 and 2 as they usually contain the TMT excess and other contaminants.
49. Repeat the run with a standard and continue running the following samples intercalating with
standard runs.
Note:Concatenate samples so that each contains eluted fractions collected at different points
in the run. For example, fraction 3 would contain fractions eluted at 3, 23, 43 and 63 min.
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50. Vacuum dry the concatenated fractions.
Pause point: Concatenated fractions can be stored at 20C.
51. Mass spectrometry analysis was performed using a nanoflow LC system (Ultimate 3000, Thermo)
coupled to a Q Exactive HF Orbitrap Mass Spectrometer (Thermo).
Note: The HPLC is equipped with a trap column switched in-line with a resolving column in
order to protect it from salts and other interfering compounds and to concentrate the pep-
tides before LC-MS/MS.
52. The mass spectrometer must be calibrated prior to analysis of samples.
53. Resuspend the concatenated samples in 0.1% FA (10 mL) and then load 1 mL aliquots (at 5 mLmin-
1) onto the trap column previously equilibrated with 95% Buffer C (0.1% FA) and 5% Buffer D
(0.1% FA in 90% ACN). Once samples are loaded, wash the column for 5 min with 5% Buffer
D at 5 mL min1.
54. Connect the trap column to the resolving column and elute peptides at 300 nL min1 with a
linear gradient (5% Buffer C for fractions 1–10, 7% for fractions 11–20, up to 35% Buffer C
over 130 min, and then to 98% Buffer C at 132 min). Wash the column with 98% Buffer C for
20 min and then re-equilibrate in 5% Buffer C for 17 min.
55. Use Q Exactive HF in data-dependent mode using the following setup:
a. MS1 scan cycles m/z range from 335–1800, with a maximum ion injection time of 50 ms, a
resolution of 120,000 and automatic gain control (AGC) value of 3 3 106
b. Followed by 15 sequential dependent MS2 scans with an isolation window set to 0.7 Da, res-
olution at 60,000, maximum ion injection time at 200 ms and AGC 1 3 105.
Protein search, thermal proteome profiling, and hit selection
Timing: 2 days
This section describes the bioinformatic steps needed to find and quantify the proteins in the sample
from the MS spectra. This section also outlines how to generate melt curves for every identified pro-
tein and to confidently identify proteins whose thermal stability has been altered in the presence of
the test compound.
56. Place the RAW data files from MS analysis in a folder and open MaxQuant software (version
1.6.17.0).
57. Download the Leishmania donovani BPK282A1 proteome FASTA file (‘‘annotated proteins’’)
from TriTrypDB.org.
Note: Other software can be used for this step (e.g. Thermo Proteome Discoverer).
Optional: TMT labelling efficiency can be checked at this point using the parameters detailed
below but by changing TMT reporters from fixed to variable modification. This can be done in
the ‘‘Configuration’’ tab in MaxQuant. The ‘‘Type’’ of experiment in the Group-specific param-
eters tab should also be set toMS1. TMT labelling efficiency can be performed on an aliquot of
the sample prior to fractionation to ensure sufficient labelling before further analysis.
58. Use default settings except for the following:
a. In the ‘‘Raw data’’ tab, RAW files are loaded and labeled according to their condition and
replicate for example ‘‘control_a’’, ‘‘control_b’’, ‘‘treated_a’’, ‘‘treated_b’’ using the ‘‘Set
experiment’’ button. Fraction number can be selected for each of them using the ‘‘Set frac-
tion’’ button and typing 1 to 20. Reference channel should be set to ‘‘1’’ in all samples.
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b. In Group-specific parameters:
i. Set Reporter ion MS2 under ‘‘Type’’ and choose the 10plex TMT option.
Change the correction factors in the table that will appear below according to the Re-
porter ion isotopic distributions table in the TMT10plex product data sheet.
ii. Choose Oxidation (M), Acetyl (Protein N-term), Dioxidation (W), Deamidation (NW) and
Gln->Pyro-Glu as variable modifications and Carbamidomethyl (C) as fixed modification
under ‘‘Modifications’’.
iii. Select Trypsin/P and LysC/P enzymes under ‘‘Digestion’’
c. In Global parameters:
i. Add the FASTA file containing the protein sequences in the ‘‘Sequences’’ tab.
ii. Set FTMS MS/MS Match tolerance to 10 ppm and ITMS MS/MS Match tolerance to
0.06 Da in the ‘‘MS/MS analyzer’’ tab.
iii. Activate the ‘‘Match between runs’’ option in the ‘‘Identification’’ tab.
d. Set the number of processors according to the capabilities of your system.
Note: Analysis time is approximately 20 h using a 28-core computer.
59. Pick the ‘‘proteinGroups.txt’’ file located in the combined/txt/ folder.
60. Open R studio and create a new project in a new folder.
61. Copy the ‘‘proteinGroups.txt’’ file, the ‘‘TPP_config-txt’’ file and the script file ‘‘StarProto-
colsTPP.R’’ in the project folder. These can be downloaded from https://github.com/
vcorpaslopez/StarProtocolsTPP.
62. If not installed, install Bioconductor and other auxiliary packages by running lines annotated in
#step 62 of the script file ‘‘StarProtocolsTPP.R’’.
63. Install and load the TPP package (version 3.16.2) by running the lines annotated in #step 63 of
the afore mentioned script file.
64. Extract the relevant columns by running lines annotated in #step 64 of the script file.
65. Check the quality of the experiment by running lines in #step 65 of the script file. This step will
produce box plots of relative protein abundance for both replicas of the two conditions. These
plots should show a reduction in median protein abundance following a decreasing sigmoidal
pattern as temperature increases and a plateau around 0.15–0.10 protein abundance from
61C. Troubleshooting 3.
66. Run lines in #step 66 of the script file to calculate the proteome coverage, a message should
appear in the console stating the proteome coverage calculated from the number of protein
groups identified. Proteome coverage should be higher than 60% of the theoretical proteome.
Troubleshooting 4.
67. Load the experiment files in the environment using lines in #step 67 of the script file.
68. Load the temperature setup running lines in #step 68 of the script file, this will load the file
‘‘TPP_config.txt’’.
69. Start the workflow running lines in #step 69 of the script file. This will run the entire work-flow, the
following modifications can be made:
a. nCores = 1, can be changed to the system capabilities.
b. normalize = TRUE or FALSE, to apply normalization or not (default is TRUE).
c. plotCurves=TRUE or FALSE, to plot the melting curves, reducing time if FALSE (default is
TRUE).
d. pValFilter = list(minR2 = 0.8, maxPlateau = 0.4), states the requirements of the curve fitting
parameters for p-value calculation. Can be changed to be more restrictive.
70. Run lines in #step 70 of the script file to create a file containing the Tm targets of the experiment.
This will create a .CSV file with the Tm targets (‘‘Tm_targets.csv’’).
71. Run lines in #step 71 of the script file to create a file containing the NPARC targets of the exper-
iment. This will create a .CSV file with the NPARC targets (‘‘NPARC_targets.csv’’). Adjust the
value in line 67 to change the p-value threshold (default 0.01, p_adj_NPARC<0.01).
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72. Full results can be viewed in the file ‘‘results_TPP_TR.xlsx’’ in the ‘‘analysis’’ folder. This excel file
contains links to themelting curves (Tmmethod) and splines (NPARCmethod) .PDF files. Melting
curve files can also be found in the analysis/Melting_Curves folder, there is a file for each protein
plotted. Troubleshooting 5.
73. In order to obtain high confidence target candidates, two independent experiments should be
performed. Any target that is identified as target via Tm analysis in both experiments (with similar
melting curve behavior), should be considered a high confidence target. Similarly, any target
considered a NPARC target with a 0.01 confidence level in both experiments (with similar
melting curve behavior), should also be considered a high confidence target.
74. To avoid missing potential targets, we recommend visually cross-checking Tm and NPARC tar-
gets from one experiment with their counterparts in the second experiment. This is particularly
important for Tm targets as some proteins may not match the statistical assumptionsmade in this
data analysis programme.
Optional: It is up to the user to reduce the stringency of the analysis modifying different pa-
rameters in step 69 or reducing stringency (increasing p-value threshold) in step 71. Targets
found by modifying these parameters should not be considered high confidence though,
but this can assist in avoiding false negatives.
75. The file ‘‘QCplots.pdf’’ in the ‘‘analysis’’ folder shows quality control plots of the process. Check
that the normalization curves have a R2 value greater than 0.90.
EXPECTED OUTCOMES
A clear melting curve should be seen after plotting the protein concentration values of the Bradford
assay (Step 12). Figure 1 shows a typical protein abundance over temperature plot from one control
sample.
The chromatogram produced in the HPLC analysis (steps 46–49) is shown in Figure 2. This graph
shows the UV intensity at 220 nm wavelength over time (80 min collection time). Good quality peaks
are defined by narrow width and high resolution. Presence of wide peaks or loss of resolution (i.e.,
peaks merge) may indicate the sample is contaminated, with detergent or other reagents, alterna-
tive column should be changed. Peaks in min 1–2 correspond to salts and free TMTs and should be
Figure 1. Representative results of Bradford assay to determine protein concentration
The graph shows protein abundance (%) over temperature (C) of the Bradford assay in step 14.
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discarded. The final peak (min 80) contains potential contaminants and undigested material and
should also be discarded.
Shown in Figure 3 is a QC plot of data generated in step 65. It shows the median protein abundance
for each temperature, including the distribution of data. Median protein abundance should indicate
a clear melt curve (as seen in Figure 3) and the protein abundance in the last temperature should be
no higher than 0.2.
Figure 4 shows the melting curves of a stabilized protein target (Leishmania donovani
LdBPK_060670.1 lanosterol synthase, putative) generated after running the TPP workflow. These
melting curves are relevant for the Tmmethod. A clear melting temperature difference is evident be-
tween the control (dashed lines) and the treated (solid lines) melting curves in both replicates (green
and purple).
Figure 5 shows the melting curves for the same target for the NPARC analysis, displaying the null
model of the analysis (that assumes that the treatment has no effect over the melting behavior)
and the alternative model (treated, orange; and control, gray) that assumes that the treatment
affects the melting behavior. The image shows how the experimental data (circles for the first and
triangles for the second replicate) adjust much better to the alternative model curves and the sub-
sequent adjusted p-value (‘‘p.adj’’ in the upper right corner).
QUANTIFICATION AND STATISTICAL ANALYSIS
The protocol described above details two different data analysis methods to identify and prioritize
protein targets. The original method (Franken et al., 2015), which we call the Tm method, was pub-
lished alongside the first TPP publication (Savitski et al., 2014). Here, protein melting curves are
fitted to a sigmoidal trend and the melting temperature (Tm, temperature at which 50% of protein
is denatured) is estimated for the treated and control samples (in duplicate) and the melting point
shift (DTm) is calculated for both replicates. Next, a z-test is run in order to determine which DTm’s
are statistically significant. The workflow then picks those proteins with two significant (FDR-adjusted
p-value <0.2) Tm shifts that also fulfill certain assumptions (detailed in the original paper). As shown
in step 71d, some filters can be modified by the user to decide which proteins undergo p-value
calculation, like R2 of the curve and plateau.
The alternative NPARC data analysis method was described more recently (Childs et al., 2019) and
does not rely on the Tm of the melting curve. In this case, the workflow estimates the goodness of
Figure 2. Representative HPLC chromatogram
The graph shows UV absorbance at 220 nm (expressed in milli-arbitrary units) over retention time (min).
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fit of the data to two different models: a null model that assumes that treatment has no effect on
the melting behaviors; and an alternative model that assumes that treatment has an effect. The
program then calculates a F statistic based on the difference between experimental data and
the two model and produces a FDR-adjusted p-value. This method is very useful in reducing false
negatives and to identify proteins with non-canonical melting behavior or a Tm greater than the
specified temperature range. Such targets would not be identified via the standard Tm method.
In the final steps of the protocol, we summarize the strategies we follow to identify potential
drug targets after performing two independent experiments each comprising two technical repli-
cates. More information about the statistical analysis can be found in the original TPP and NPARC
papers.
LIMITATIONS
TPP is a very powerful technique that can be used to identify the targets of phenotypically
active compounds; however, its power relies on the thermal stabilization of proteins upon
drug binding. However, some proteins are not susceptible to thermal stabilization or de-
stabilization so would not be identified by this approach. The affinity of a specific drug for its
target may also affect the level of thermal-shift observed. Some protein targets may not be
abundant enough to be reliably identified and quantified using mass spectrometry, since their
abundance would be obscured by other more abundant proteins. It should also be noted that
targets within large protein complexes, such as the proteasome, may be more challenging to iden-
tify. The same may also be true for targets that are integral membrane proteins. Finally, this




Protein yield not sufficient for the assay (step 7)
Potential solution
If protein yield is lower than 4 mg using the suggested protocol, increase the scale of the initial cell
cultures. Do not proceed with the thermal shift assay part of the protocol using samples with a
Figure 3. Median abundance box plot of proteins quantified through LC-MS/MS
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protein concentration < 0.5 mg mL1, since at lower concentrations proteins may fail to aggregate
and precipitate. It is important to check the pH of the Lysis Buffer and to use fresh components when
preparing the buffer, particularly protease inhibitors.
Problem 2
Unexpected protein concentration results in the Bradford assay (step 12).
Potential solution
If the protein concentration plot does not resemble that shown in Figure 1, repeat the Bradford
assay. If problem persists, validate the set temperatures in the thermal cycler. When harvesting
the supernatant after ultracentrifugation steps be careful not to be greedy. Attempting to recover
all the supernatant can risk disturbing the pellet and potential affect the quality and/or accuracy
of the results.
Problem 3
Unexpected median protein abundance (step 65)
Potential solution
If median protein abundance does not resemble that shown in Figure 3, check TMT labeling effi-
ciency. Low TMT efficiency (<98%) will affect protein quantitation. If TMT labeling efficiency is
low, conditions during labeling should be checked (TMT reagent/protein ratio, pH of the reaction,
TMT expiry date and storage conditions).
Problem 4
Low proteome coverage (step 66).
Potential solution
If the detected proteome coverage is lower than 60% compared to the theoretical proteome, check
efficiency of the digestion steps.
Problem 5
High variability between replicates (step 72).
Figure 4. Melting curves for a protein target generated in the TPP workflow. The graph shows the non-denatured
fraction (protein abundance) over temperature (C) of control (dashed lines) and treated (solid lines) melting curves,
two replicates (green and purple lines).
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Potential solution
If there is a large and consistent difference between the replicates in the control or treated samples
(either Tm between replicates or experimental data points), one solution is to process both replicas
at the same time. It is particularly important to fractionate the 4 samples in the HPLC in the same
session and run the 96 fractions in the mass spectrometer without interruptions (i.e., running other
samples). These will greatly improve the reproducibility of the data.
RESOURCE AVAILABILITY
Lead contact
Further information and requests for resources and reagents should be directed to and will be ful-
filled by the lead contact, Dr Susan Wyllie (s.wyllie@dundee.ac.uk).
Materials availability
All reasonable requests for materials used in this study will be considered.
Data and code availability
The mass spectrometry raw files and their associated MaxQuant output files generated during this
study are available at ProteomeXchange Consortium (Vizcaino et al., 2014) via the PRIDE partner re-
pository (http://www.ebi.ac.uk/pride/archive/), under the identifier PRIDE: PXD023780 as listed in
the key resources table.
All the programming functions required to perform this analysis can be found in TPP, an R package
(Childs et al., 2020) or available for download at https://www.bioconductor.org/packages/release/
bioc/html/TPP.html.
Figure 5. Melting curves for a protein target generated in the NPARC part of the TPP workflow
The graph shows the non-denatured fraction (protein abundance) over temperature (C) of a protein, displaying the
null model of the analysis that assumes that the treatment has no effect over the melting behavior (black line) and the
alternative model (treated, orange; and control, gray) that assumes that the treatment affects the melting behavior.
Experimental data is shown as dots (circles for the first and triangles for the second replicate). The adjusted p-value of
the analysis is shown as ‘‘p.adj’’ in the upper right corner.
ll
OPEN ACCESS
STAR Protocols 2, 100704, September 17, 2021 17
Protocol
A wrapper script to follow these steps can be downloaded at https://github.com/vcorpaslopez/
StarProtocolsTPP.
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